Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 7.90
-0.01 (-0.13%)
Aug 28, 2025, 9:45 AM HKT
Sino Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 30,567 | 28,866 | 26,199 | 26,026 | 26,861 | 23,647 | Upgrade | |
Revenue Growth (YoY) | 13.23% | 10.18% | 0.67% | -3.11% | 13.59% | -2.42% | Upgrade |
Cost of Revenue | 5,573 | 5,336 | 4,990 | 4,488 | 5,332 | 5,182 | Upgrade |
Gross Profit | 24,994 | 23,530 | 21,210 | 21,539 | 21,529 | 18,465 | Upgrade |
Selling, General & Admin | 12,855 | 12,159 | 11,067 | 11,709 | 12,704 | 11,629 | Upgrade |
Other Operating Expenses | 6,399 | 5,569 | 4,704 | 4,444 | 4,193 | 2,738 | Upgrade |
Operating Expenses | 19,254 | 17,729 | 15,770 | 16,153 | 16,896 | 14,366 | Upgrade |
Operating Income | 5,740 | 5,801 | 5,439 | 5,386 | 4,633 | 4,098 | Upgrade |
Interest Expense | -264.58 | -295.12 | -495.24 | -429.49 | -308.62 | -323.37 | Upgrade |
Interest & Investment Income | 3,018 | 1,347 | 611.38 | 472.38 | 559.89 | 520.28 | Upgrade |
Earnings From Equity Investments | -30.07 | -118.3 | -525.71 | -152.98 | 13,631 | -3.23 | Upgrade |
Currency Exchange Gain (Loss) | 36.45 | -123.41 | -96.02 | 138.22 | 292.3 | - | Upgrade |
Other Non Operating Income (Expenses) | 249.39 | 359.43 | 570.2 | 185.84 | 488.2 | 272.92 | Upgrade |
EBT Excluding Unusual Items | 8,750 | 6,971 | 5,504 | 5,600 | 19,295 | 4,565 | Upgrade |
Impairment of Goodwill | -18.62 | -18.62 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -908.33 | -1,483 | -46.9 | -449.08 | -265.38 | 443.44 | Upgrade |
Gain (Loss) on Sale of Assets | 162.64 | 163.47 | 57.02 | 3.47 | -4.28 | 4.58 | Upgrade |
Asset Writedown | -286.81 | -286.81 | - | -19.4 | -441.1 | - | Upgrade |
Other Unusual Items | -68.09 | -68.09 | -104.06 | 80.08 | -12.02 | - | Upgrade |
Pretax Income | 7,630 | 5,277 | 5,410 | 5,215 | 18,573 | 5,013 | Upgrade |
Income Tax Expense | 860.15 | 492.92 | 797.27 | 696.72 | 1,958 | 672.38 | Upgrade |
Earnings From Continuing Operations | 6,770 | 4,785 | 4,613 | 4,518 | 16,615 | 4,341 | Upgrade |
Earnings From Discontinued Operations | -26.63 | 1,580 | 484.76 | 484.47 | - | - | Upgrade |
Net Income to Company | 6,744 | 6,365 | 5,097 | 5,003 | 16,615 | 4,341 | Upgrade |
Minority Interest in Earnings | -2,872 | -2,865 | -2,765 | -2,459 | -2,006 | -1,570 | Upgrade |
Net Income | 3,871 | 3,500 | 2,332 | 2,544 | 14,608 | 2,771 | Upgrade |
Net Income to Common | 3,871 | 3,500 | 2,332 | 2,544 | 14,608 | 2,771 | Upgrade |
Net Income Growth | 20.56% | 50.08% | -8.32% | -82.59% | 427.17% | 0.35% | Upgrade |
Shares Outstanding (Basic) | 18,091 | 18,294 | 18,529 | 18,622 | 18,769 | 18,800 | Upgrade |
Shares Outstanding (Diluted) | 18,103 | 18,295 | 18,529 | 19,017 | 19,283 | 18,800 | Upgrade |
Shares Change (YoY) | -2.10% | -1.26% | -2.57% | -1.38% | 2.57% | -0.06% | Upgrade |
EPS (Basic) | 0.21 | 0.19 | 0.13 | 0.14 | 0.78 | 0.15 | Upgrade |
EPS (Diluted) | 0.21 | 0.19 | 0.13 | 0.12 | 0.73 | 0.15 | Upgrade |
EPS Growth | 23.13% | 51.97% | 3.55% | -83.41% | 397.00% | 0.40% | Upgrade |
Free Cash Flow | - | 5,655 | 4,998 | 5,022 | 3,652 | 3,901 | Upgrade |
Free Cash Flow Per Share | - | 0.31 | 0.27 | 0.26 | 0.19 | 0.21 | Upgrade |
Dividend Per Share | 0.083 | 0.065 | 0.044 | 0.106 | 0.065 | 0.062 | Upgrade |
Dividend Growth | 65.66% | 46.97% | -58.16% | 62.87% | 5.59% | 29.39% | Upgrade |
Gross Margin | 81.77% | 81.51% | 80.95% | 82.76% | 80.15% | 78.09% | Upgrade |
Operating Margin | 18.78% | 20.10% | 20.76% | 20.69% | 17.25% | 17.33% | Upgrade |
Profit Margin | 12.67% | 12.12% | 8.90% | 9.77% | 54.38% | 11.72% | Upgrade |
Free Cash Flow Margin | - | 19.59% | 19.08% | 19.30% | 13.60% | 16.50% | Upgrade |
EBITDA | 6,896 | 6,893 | 6,379 | 6,254 | 5,453 | 5,661 | Upgrade |
EBITDA Margin | 22.56% | 23.88% | 24.35% | 24.03% | 20.30% | 23.94% | Upgrade |
D&A For EBITDA | 1,156 | 1,092 | 939.85 | 868.56 | 820.57 | 1,562 | Upgrade |
EBIT | 5,740 | 5,801 | 5,439 | 5,386 | 4,633 | 4,098 | Upgrade |
EBIT Margin | 18.78% | 20.10% | 20.76% | 20.69% | 17.25% | 17.33% | Upgrade |
Effective Tax Rate | 11.27% | 9.34% | 14.74% | 13.36% | 10.54% | 13.41% | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.